UK diagnostics company Owlstone Medical was among winners of a $1 million award that will help develop new devices for patients with idiopathic pulmonary fibrosis (IPF).
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
